



SEMPERIT GROUP Q1 2022 INVESTOR PRESENTATION

Karl Haider, CEO

Petra Preining, CFO

18 May 2022



Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.11)

Outlook (p.21)

Appendix (p.24)



Q1 2022 Highlights



Strong Q1'22 results against exogenous economic shocks; resilience in Industrial and normalisation of special cycle in Medical Sector



Industrial Sector: strong order book and sales; headwinds from input prices – close collaboration of supply chain management, procurement, R&D and production



Further price decline for protective gloves albeit still above pre-Corona level, margins at the markets are starting to stabilise



Proactive and timely price adjustments of varying scale depending on the segment



Strong balance sheet supports aspiration for future organic and inorganic growth – sales to Russia and Belarus suspended on 18 March, stronger position in North America





Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.11)


Outlook (p.21)

Appendix (p.24)




Industrial Sector more resilient with continuing top-line growth

Revenues in EUR m
Q1'19 – Q1'22



Quarterly development of EBITDA (in EURm) and EBITDA margin (in%)
since 2019




- Revenues increased by 31%, EBITDA up by 28% yoy – margins remain under pressure due to cost inflation
- Defending margins through proactive price increases and ongoing focus on cost control together with continuous efficiency improvements




Semperflex Q1 2022

Continuing revenue growth and stronger margins

Semperflex



Q1 2022 vs. Q1 2021



- Order book and revenues well above pre-Corona level
- Outstanding operating performance despite supply constraints for raw materials and high input cost inflation
- High capacity utilisation in Odry
- Strong US order book and sales despite supply constraints







Sempertrans Q1 2022

First visible signs of segment's recovery reflected in results

Sempertrans



Q1 2022 vs. Q1 2021



- Mining industry further recovered on the back of higher raw materials which in turn stimulated new investments and maintenance
- Top line and profitability slightly improving, despite delays in realisation due to congested logistics
- Positive margin development
- Segment still receives highest management attention
- Order book doubled YOY as replacement orders increased and new projects started to gain momentum



¹ Q1'19 EBITDA: positive effects of € 1.3m profit from sale of assets of closed factory in China



² Q3'21 EBITDA: positive effect of € 3.7m from recycling of foreign exchange differences




Sempers seal Q1 2022

Margins under pressure due to time lag in in passing on higher costs


Sempers seal



Q1 2022 vs. Q1 2021



- Good order intake, order book above Q1'21
- Outstanding top-line growth in difficult operational environment
- Hesitant general market sentiment with respect to price increases
- USA: ramp up of new production site in Newnan, Georgia in Q1'22








Semperform Q1 2022

Continuing top-line growth – but margin pressure due to cost inflation

Semperform



Q1 2022 vs. Q1 2021



- Strong order intake continues to keep order book level above comparable periods
- Shift in product mix: high-margin BU Special Applications (ski tourism) is picking up towards end of the quarter
- Strong turnover, especially at the BUs Engineered Solutions and Special Applications
- Despite price increases, higher input costs lead to lower margins in Q1'22






Medical Sector / Sempermed segment Q1 2022

Further price normalisation while still above pre-Corona level

Sempermed



Q1 2022 vs. Q1 2021

Revenue current period

106

Revenue comparable period

193

EBITDA current period

13

EBITDA comparable period

105

in € m

- Change towards buyers' instead of sellers' market
- Margins in the broader markets start to stabilise towards pre-Corona levels
- In turn, Sempermed margin still well-above pre-Corona level due to prior restructuring effort
- Strong order book – above pre-corona level
- P7+ plant – project finalised in time and on budget



¹ Q3'19 EBITDA adjusted for € 4m due to the positive effect from the release of provision in Sempermed for Brazilian court case for tax liabilities



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.11)

Outlook (p.21)

Appendix (p.24)



Q1 2022 Financial Highlights



Robust industrial performance despite high inflation and supply constraints while normalisation of Covid-related special effects in Medical Sector



Working capital management: proactive inventory build-up due to Russian war in Ukraine and continuing price increases



Efficiency and cost measures remain key management focus against exogenous shocks of high inflation, logistical constraints and wartime impact



Higher investment levels to support future growth together with energy efficiency and IT upgrade in 2022



Strong balance sheet and high liquidity support aspiration for future organic and inorganic growth




2022 EBITDA is expected to be significantly below the average market consensus (as of early March 2022) due to Russia-Ukraine conflict





Revenue development




% change of each segment / sector refers to 2022 vs. 2021.



Resilient performance in Industrial offset by disproportionate decline in Medical


in € m



	Q1 2021	Semperfex	Sempertrans	Semperseal	Semperform	Sempermed	Corporate	Q1 2022
EBITDA Q1 2021	122.2	12.3	1.0	4.2	3.1	105.3	-3.7	
EBITDA Q1 2022		19.6	1.3	2.4	3.2	13.3	-3.2	36.5
EBITDA margin Q1 2022		24.5%	4.5%	6.5%	12.2%	12.6%	—	13.2%



Major drivers of operating performance



in € million



Overview of key financial KPIs, Q1 2019 – Q1 2022

	Q1 2019	Q1 2020	Q1 2021	Q1 2022
EBITDA, in € m	16.5	16.9	122.2	36.5
EBITDA margin, in %	7.7	8.5	37.8	13.2
EBIT, in € m	7.8	9.8	110.8	23.7
EBIT margin, in %	3.7	4.9	34.3	8.6
Earnings after tax, in € m	3.2	-1.7	85.5	15.5
Free Cashflow, in € m	18.6	23.3	38.8	-0.1
CAPEX, in € m	16.2	6.8	10.2	17.2




Quarterly CAPEX development 2020-2022

- Tangible CAPEX increase through the cycle with post-Covid catch-up effect due to supply chain constraints
- Outlook 2022: planned to be approximately at 2021 level
- Industrial Sector: increasing focus on growth CAPEX

CAPEX per segment


in € m





Free cash flow development

- Decline in operating cash flow implies normalisation of Covid-related special effect in Medical Sector
- Operating cash flow impacted by proactive inventory build up
- Investment cash flow driven by increased CAPEX level




¹ Q1 2021 free cash flow adjusted for investments in money market funds shares (€ -20m) included in investment cash flow (in total € -31m)



Working Capital overview

Components of Working Capital

in € m




¹ Trade Working Capital in % of LTM revenues



Balance sheet structure and financial profile

Balance sheet structure

Balance sheet 31/03/2022: € 997m
Balance sheet 31/12/2021: € 959m



Financial profile as of 31 March 2022

- **Cash and cash equivalents** at € 231m
- **Unused credit facilities** total € 90m
- **Corporate Schuldschein loan** at € 87m
- **“Net debt” remains net cash** at € 144m, Net debt / EBITDA below zero (YE'21: below zero)
- **Equity ratio** of 56.2% (YE'21: 56.3%)
- **Dividend** of EUR 1.50 for 2021 approved by AGM on April 27



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.13)

Outlook (p.21)

Appendix (p.24)



Management Agenda and Expectations for 2022

Starting base line in 2022

Protective glove prices further declining from plateau in Q2'21

Focus on strategic growth of the Industrial Sector

Strict cost management to maintain competitive position

accelerated in Q1'22

Geopolitical crisis

Additional supply constraints due to lockdowns in China

Strong focus on cost inflation, FX, working capital

Expectations for 2022

Geopolitical crisis potentially undermines gas supply and worsened raw materials' availability, implying the need for higher inventory buffers especially in Europe

Strict lockdown policy in China impacts global supply chains & raw materials' availability, thus increasing the global logistical challenge

Market dynamics might deviate from current supply & demand assumptions – with cost inflation accelerating in H2 2022 and growth slowing further

Consequently, 2022 EBITDA is expected to be significantly below the average market consensus (early March '22 € 100-120m) due to Russia-Ukraine conflict

Strong focus on internal management capability against exogenous disruption (raw materials, energy, logistics and labour); stronger position in US in pursuit of strategic diversification



Contact and financial calendar

Investor Relations Semperit

Judit Helenyi, Director Investor Relations

+43 1 79777 - 310

www.semperitgroup.com/en/ir

Am Belvedere 10

1100 Vienna, Austria

Financial Calendar 2022

18.5.2022

Report on Q1 2022

17.8.2022

Half-year financial report 2022

16.11.2022

Report on Q1-3 2022

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.13)

Outlook (p.21)

Appendix (p.24)



Sectors and Group: Q1 2022 vs Q1 2021

	Industrial Sector			Medical Sector			Semperit Group		
in EUR m	Q1 2022	Q1 2021	%	Q1 2022	Q1 2021	%	Q1 2022	Q1 2021	%
Revenue	171.0	130.1	+31.4%	106.1	192.9	-45.0%	277.0	323.1	-14.2%
EBITDA	26.4	20.6	+28.1%	13.3	105.3	-87.3%	36.5	122.2	-70.1%
EBITDA margin	15.5%	15.9%	-0.4 PP	12.6%	54.6%	-42.0 PP	13.2%	37.8%	-24.6 PP
EBIT	19.6	14.5	+35.0%	7.6	100.2	-92.4%	23.7	110.8	-78.6%
EBIT margin	11.5%	11.2%	+0.3 PP	7.2%	52.0%	-44.8 PP	8.6%	34.3%	-25.7 PP
Earnings after tax	-	-	-	-	-	-	15.5	85.5	-81.8%
Earnings per share in EUR	-	-	-	-	-	-	0.75	4.13	-81.8%
Additions in tangible and intangible assets	4.3	6.4	-37.2%	4.5	5.1	-11.2%	10.0	12.2	-17.9%
Employees		3,557			3,301			7,001	

Figures of Semperit Group also contain intercompany consolidation and the results of the Corporate Segment




Semperit Group adj. where applicable


Semperit Group adj. where applicable

in EUR m	Q1 2019	Q2 2019	Q3 2019 adj. ¹⁾	Q4 2019 adj. ²⁾	FY 2019	Q1 2020	Q2 2020 adj. ³⁾	Q3 2020 adj. ⁴⁾	Q4 2020 adj.	FY 2020 adj. ⁵⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022
Revenue	212.9	224.4	214.9	188.3	840.6	199.1	219.8	238.2	270.5	927.6	323.1	337.7	265.3	256.1	1,182.2	277.0
EBITDA	16.5	22.7	17.3	7.4	63.8	16.9	40.7	60.9	90.0	208.6	122.2	125.3	76.8	37.5	361.8	36.5
EBITDA margin	7.7%	10.1%	8.0%	3.9%	7.6%	8.5%	18.5%	25.6%	33.3%	22.5%	37.8%	37.1%	28.9%	14.6%	30.6%	13.2%
EBIT	7.8	13.1	8.1	-0.7	28.2	9.8	33.6	49.2	78.8	171.4	110.8	113.8	65.4	25.0	315.0	23.7
EBIT margin	3.7%	5.8%	3.8%	-0.4%	3.4%	4.9%	15.3%	20.7%	29.1%	18.5%	34.3%	33.7%	24.7%	9.8%	26.6%	8.6%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Q3 2019 adjusted for negative one-off effect of € 47m from impairment of Sempermed (adj. for EBIT) and € 4m (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities. ²⁾ Q4 2019: impairment figure of Q3 2019 stepped up by € 2m due to additions to assets and FY deviations ³⁾ Q2 2020: adjusted for the positive one-off effect from the write-up in the Sempermed segment (EBIT: EUR 88.8 million) and the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect –20.0 Million EUR) ⁴⁾ Q3 2020: adjusted for the special effect from the write-up in the Sempermed segment (EBIT: EUR –2.1 million) and the special effect from the impairment in the Sempertrans segment (EBIT effect EUR +0.1 million). ⁵⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR –19.8 million)



Semperflex and Sempertrans (adj. where applicable)

Semperflex (Hoses)

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022
in EUR m																
Revenue	61.1	59.7	53.8	48.0	222.7	46.8	51.5	46.6	45.0	189.9	54.7	59.7	57.7	68.4	240.5	79.8
EBITDA	13.9	14.5	10.8	8.7	47.9	9.3	14.0	11.4	7.2	41.9	12.3	13.9	11.2	13.9	51.3	19.6
EBITDA margin	22.8%	24.3%	20.1%	18.1%	21.5%	19.9%	27.2%	24.5%	16.0%	22.1%	22.5%	23.3%	19.3%	20.4%	21.3%	24.5%
EBIT	11.1	11.5	7.7	5.7	36.0	6.5	11.2	8.7	4.5	30.9	9.6	11.1	8.4	11.0	40.0	16.6
EBIT margin	18.2%	19.2%	14.3%	11.9%	16.2%	13.9%	21.8%	18.6%	10.0%	16.3%	17.5%	18.5%	14.5%	16.1%	16.6%	20.8%

Sempertrans (Conveyor belts)

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020 adj. ¹⁾	Q3 2020 adj. ²⁾	Q4 2020 ³⁾	FY 2020 adj. ⁴⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022
in EUR m																
Revenue	30.4	37.8	35.1	30.6	134.0	29.5	32.5	28.4	22.7	113.1	26.9	24.2	28.0	25.3	104.5	28.3
EBITDA	2.7	5.4	4.6	0.8	13.5	1.6	5.0	2.1	0.0	8.7	1.0	0.8	4.7	0.4	6.8	1.3
EBITDA margin	9.0%	14.2%	13.1%	2.5%	10.1%	5.4%	15.4%	7.6%	0.0%	7.7%	3.8%	3.3%	16.7%	1.4%	6.6%	4.5%
EBIT	1.8	3.8	3.6	-0.3	8.9	0.6	3.9	1.4	-0.6	4.9	0.2	-0.1	3.8	-0.7	3.2	0.3
EBIT margin	6.0%	10.0%	10.4%	-0.9%	6.7%	1.9%	11.9%	5.0%	-2.6%	4.3%	0.7%	-0.2%	13.6%	-2.9%	3.1%	1.2%

¹⁾ Q2 2020: adjusted for the negative one-off effect from the impairment in the Sempertans segment (EBIT effect: EUR 20.0 million).

²⁾ Q3 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

³⁾ Q4 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

⁴⁾ 2020: Adjusted for the negative one-off effect of the impairment in the Sempertrans segment (2020 EBIT effect: EUR 19.8 million)



Semperform and Semperseal (adj. where applicable)

Semperform (Window and door profiles, Handrails) - before 2020

in EUR m	FY 2017 adj.	Q1 2018	Q2 2018	Q3 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
Revenue	185.0	47.5	50.7	50.3	192.2	49.9	50.5	47.8	42.4	190.6
EBITDA	21.5	4.5	7.3	6.2	21.9	7.9	8.3	6.6	3.3	26.0
EBITDA margin	11.6%	9.6%	14.4%	12.2%	11.4%	15.7%	16.4%	13.8%	7.8%	13.6%
EBIT	13.3	2.4	5.1	4.2	13.2	5.4	5.9	4.2	0.5	16.0
EBIT margin	7.2%	5.0%	10.1%	8.4%	6.9%	10.9%	11.6%	8.7%	1.1%	8.4%

Semperform (Window and door profiles, Handrails) - after 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022
Revenue	22.4	24.6	22.3	21.8	91.1	19.9	21.9	20.4	19.6	81.8	19.8	23.6	23.3	23.9	90.6	26.2
EBITDA	4.0	4.8	4.1	2.7	15.6	3.5	5.0	4.0	2.5	15.0	3.1	3.6	3.3	2.5	12.4	3.2
EBITDA margin	17.7%	19.6%	18.4%	12.2%	17.1%	17.5%	22.6%	19.6%	12.9%	18.3%	15.4%	15.2%	14.1%	10.3%	13.7%	12.2%
EBIT	3.1	4.0	3.2	1.7	12.0	2.6	4.1	3.1	1.6	11.3	2.1	2.6	2.3	1.4	8.5	2.1
EBIT margin	13.9%	16.1%	14.3%	7.7%	13.1%	12.9%	18.5%	15.1%	8.0%	13.8%	10.8%	11.2%	10.0%	6.0%	9.4%	8.2%

Sempersal (Profiles and Rubber Sheeting) starting in 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022
Revenue	27.5	25.8	25.6	20.5	99.5	25.4	21.7	24.4	22.2	93.6	28.7	30.3	32.4	29.1	120.5	36.6
EBITDA	3.9	3.4	2.5	0.6	10.4	3.3	3.2	2.9	1.7	11.0	4.2	2.4	4.1	0.9	11.6	2.4
EBITDA margin	14.1%	13.2%	9.8%	3.0%	10.5%	12.8%	14.7%	12.0%	7.5%	11.8%	14.7%	7.9%	12.6%	3.0%	9.6%	6.5%
EBIT	2.3	1.9	1.0	-1.2	4.0	1.8	1.7	1.4	0.2	5.1	2.6	0.8	2.5	-0.9	5.1	0.5
EBIT margin	8.4%	7.3%	3.9%	-5.8%	4.0%	6.9%	8.0%	5.8%	1.1%	5.5%	9.2%	2.6%	7.7%	-3.1%	4.2%	1.4%

Split of former Semperform into Sempersal and Semperform as of 1st January 2020 – historic Semperform numbers for 2019 adapted for this split accordingly



Sempermed (adj. where applicable)

Sempermed (Gloves)																
	Q1 2019	Q2 2019	Q3 2019 adj. ¹⁾	Q4 2019	FY 2019 ²⁾	Q1 2020	Q2 2020 adj. ³⁾	Q3 2020 adj. ⁴⁾	Q4 2020 ⁵⁾	FY 2020 adj. ⁶⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022
in EUR m																
Revenue	71.5	76.4	78.2	67.3	293.3	77.5	92.2	118.4	161.1	449.2	192.9	199.8	124.0	109.4	626.1	106.1
EBITDA	-0.9	0.6	1.8	-0.1	1.4	4.8	18.2	44.4	83.0	150.4	105.3	115.3	56.9	23.7	301.1	13.3
EBITDA margin	-1.2%	0.8%	2.3%	-0.1%	0.5%	6.1%	19.7%	37.5%	51.5%	33.5%	54.6%	57.7%	45.9%	21.7%	48.1%	12.6%
EBIT	-2.8	-1.4	-0.3	-0.9	-5.5	4.4	17.6	38.9	77.8	138.7	100.2	110.3	52.1	18.3	280.9	7.6
EBIT margin	-3.9%	-1.9%	-0.4%	-1.4%	-1.9%	5.5%	19.1%	32.8%	48.3%	30.9%	52.0%	55.2%	42.0%	16.7%	44.9%	7.2%

¹⁾ Q3 2019 adjusted for negative one-off effect of EUR 46.8 million from impairment of Sempermed (adj. for EBIT) and EUR 4 million (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

²⁾ 2019: adjusted for the positive one-off effect from the reversal of a provision for the tax procedure on levies in Brazil (EBITDA, EBIT: EUR 4.0 million), as well as the negative effect of the impairments for the Sempermed segment (EBIT: -48.8 million EUR)

³⁾ Q2 2020: adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT: EUR +88.8 million)

⁴⁾ Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -2.1 million)

⁵⁾ Q4 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -0.5 million)

⁶⁾ 2020: adjusted for the positive one-off effect of the reversal of impairment in the Sempermed segment (2020 EBIT effect: EUR +86.2 million)



Key figures 2011-2021

Key performance figures											
in EUR m	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016 adj. ⁴⁾	2017 adj. ⁵⁾	2018 adj. ⁶⁾	2019 adj. ⁷⁾	2020 adj. ⁸⁾	2021
Revenue	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5	840.6	927.6	1,182.2
EBITDA	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8	208.6	361.8
EBITDA margin	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%	30.6%
EBIT	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2	171.4	315.0
EBIT margin	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.6%	18.5%	26.6%
Earnings after tax	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3	-0.2	121.9	247.5
EPS²⁾, in EUR	2.52	2.25	2.65	1.85	2.26	0.74	-2.08	-1.06	-0.33	5.53	11.99
Gross cash flow	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.70	193.7	323.4
Return on equity	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%	45.7%


Balance sheet key figures											
in EUR m	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016	2017	2018	2019	2020	2021
Balance sheet total	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8	764.4	958.6
Equity²⁾	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5	237.4	332.3	540.1
Equity ratio	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%	56.3%
Investments in tangible and intangible assets	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4	47.9
Employees, at balance sheet date, FTEs	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902	6,943	6,948

¹⁾ 2011 restated (see Annual Report 2012, Notes 2.18). ²⁾ 2014 and 2015 restated. ³⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. ⁴⁾ 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ⁵⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only). ⁶⁾ FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). ⁷⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million)



Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0




Overview price indices LFO-F-NWE / wire rod

Significant increase for raw material¹⁾ used in industrial segments

Price index LFO-F-NWE



Price index wire rod



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Product / market position / segment overview, FY 2021

in EUR m

Semperit Group

Group	Industrial Sector				Medical Sector	
	Semperflex	Sempertrans	Semperform	Semperseal	Sempermed	
Revenue	1.182.2	240.5 / 20% ¹⁾	104.5 / 9% ¹⁾	90.6 / 8% ¹⁾	120.5 / 10% ¹⁾	626.1 / 53% ¹⁾
EBITDA	361.8 ²⁾	51.3	6.8	12.4	11.6	301.1
Employees	6,948 ²⁾	1,753 / 25% ³⁾	921 / 13% ³⁾	576 / 8% ³⁾	514 / 7% ³⁾	3,038 / 44% ³⁾

Products and market position

Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe
6 position globally



Conveyor belts

One of the leading suppliers of heavy-duty steel cord and textile conveyor belts



HSA* / SES**

Leading European manufacturers of moulded and extrusion products made of polymer and plastics
(handrails, cable car rings, ski foils and Engineered Solutions)



Profiles / Rubber Sheeting

Leading European manufacturer of sealing profiles and elastomer sheeting
(construction, packaging, machinery, HVAC, marine, electric systems)



Examination gloves

Among the top 15 glovemakers in the world



Surgical gloves

Among the leading companies in Europe




*Handrails, Special Applications
** Semperit Engineered Solutions

¹⁾ Revenue in % of Group revenue.
²⁾ Group figure includes corporate center of € -21m, 147 employees.
³⁾ Employees in % of Group employees.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C